Funding for this research was provided by:
(P30 CA56036, R01 CA170533)
Pharmaceutical Research and Manufacturers of America Foundation
Pennsylvania Department of Health (SAP #4100051723)
Targeted Diagnostic and Therapeutics Inc.
Margaret Q. Landenberger Research Foundation
Text and Data Mining valid from 2019-04-23
Received: 21 December 2018
Accepted: 22 March 2019
First Online: 23 April 2019
Ethics approval and consent to participate
: The study protocol and all amendments were approved by the Thomas Jefferson University Institutional Review Board (IRB# 13S.462) and Institutional Biosafety Committee (IBC). The study was conducted in accordance with the protocol, Good Clinical Practice guidelines, the ethical principles outlined in the Declaration of Helsinki, and the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. All patients provided written informed consent to participate.
: Not applicable.
: SAW was the Chair of the Data Safety Monitoring Board for the CHART-1 Trial™ sponsored by Cardio3 Biosciences, a member of the Board of Directors of Feelux Co. Ltd., and the Chair of the Scientific Advisory Board and member of the Board of Directors (both uncompensated) of Targeted Diagnostics and Therapeutics, Inc. which provided research funding that, in part, supported this work and has a license to commercialize inventions related to this work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.